Medarex Studying Ipilimumab As First-Line Treatment For Metastatic Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Medarex plans to initiate a clinical trial evaluating ipilimumab (MDX-010) in combination with chemotherapy as a first-line treatment for metastatic melanoma, the company said June 19